Skip to content
Triangle logo TriangleGet started
← Study library

NCT01231412 · REGISTRY CONDITION SEARCH

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2026-04-30

This randomized phase III trial studies how well graft-vs-host disease (GVHD) prophylaxis works in treating patients with hematologic malignancies undergoing unrelated donor peripheral blood stem cell transplant. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant (PBSCT) helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving total-body irradiation (TBI) together with fludarabine phosphate (FLU), cyclosporine (CSP), mycophenolate mofetil (MMF), or sirolimus before transplant may stop this from happening.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Patients With Grades II-IV Acute GVHD

→

outcome · POSTED

Number of Patients With Chronic Extensive GVHD

→

outcome · POSTED

Number of Patients With Grades III-IV Acute GVHD

→

outcome · POSTED

Number of Non-Relapse Mortalities

→

outcome · POSTED

Number of of Participants Surviving Overall

→

outcome · POSTED

Number of Participants With Relapse/Progression

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Ages \> 50 years with hematologic malignancies treatable by unrelated hematopoietic cell transplant (HCT) * Ages =\< 50 years of age with hematologic diseases treatable by allogeneic HCT who through pre-existing medical conditions or prior therapy are considered to be at high risk for regimen related toxicity associated with a high dose transplant (\> 40% risk of transplant related mortality \[TRM\]); this criterion can include patients with a HCT-comorbidity index (CI) score of \>= 1; transplants should be approved for these inclusion criteria by the principal investigators at the collaborating centers and at the Fred Hutchinson Cancer Research Center (FHCRC); all children \< 12 years must be discussed with the FHCRC principal investigator (PI) prior to registration * Ages =\< 50 years of age with chronic lymphocytic leukemia (CLL) * Ages =\< 50 years of age with hematologic diseases treatable by allogeneic HCT who refuse a high-dose HCT; transplants must be approved for these inclusion criteria by the principal investigators at the collaborating centers and at FHCRC * The following diseases will be permitted although other diagnoses can be considered if approved by Patient Care Conference (PCC) or the participating institutions' patient review committees and the principal investigators * Aggressive non-Hodgkin lymphomas (NHL) and other histologies such as diffuse large B cell NHL: not eligible for autologous HCT, not eligible for high-dose allogeneic HCT, or after failed autologous HCT * Mantle cell NHL: may be treated in first complete remission (CR); (diagnostic lumbar puncture \[LP\] required pre-transplant) * Low grade NHL: with \< 6 month duration of CR between courses of conventional therapy * CLL: must have either: * Failed to meet National Cancer Institute (NCI) Working Group criteria for complete or partial response after therapy with a regimen containing FLU (or another nucleoside analog, e.g. 2-Chlorodeoxyadenosine \[2-CDA\], pentostatin) or experience disease relapse within 12 months after completing therapy with a regimen containing FLU (or another nucleoside analog); * Failed FLU-cyclophosphamide (CY)-Rituximab (FCR) combination chemotherapy at any time point; or * Have "17p deletion" cytogenetic abnormality; patients should have received induction chemotherapy but could be transplanted in 1st CR; or * Patients with a diagnosis of CLL (or small lymphocytic lymphoma) or diagnosis of CLL that progresses to prolymphocytic leukemia (PLL), or T-cell CLL or PLL * Hodgkin lymphoma: must have received and failed frontline therapy * Multiple myeloma: must have received prior chemotherapy; consolidation of chemotherapy by autografting prior to nonmyeloablative HCT is permitted * Acute myeloid leukemia (AML): must have \< 5% marrow blasts at the time of transplant * Acute lymphocytic leukemia (ALL): must have \< 5% marrow blasts at the time of transplant * Chronic myeloid leukemia (CML): patients in 1st chronic phase (CP1) must have failed or be intolerant of tyrosine-kinase inhibitors (TKI); patients beyond CP1 will be accepted if they have \< 5% marrow blasts at time of transplant * Myelodysplasia (MDS)/myeloproliferative syndrome (MPS): patients must have \< 5% marrow blasts at time of transplant * Waldenstrom's macroglobulinemia: must have failed 2 courses of therapy * DONOR: FHCRC matching allowed will be grades 1.0 to 2.1: Unrelated donors who are prospectively: * Matched for human leukocyte antigen (HLA)-A, B, C, DRB1 and DQB1 by high resolution typing * Only a single allele disparity will be allowed for HLA-A, B, or C as defined by high resolution typing * DONOR: Donors are excluded when preexisting immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment; this determination is based on the standard practice of the individual institution; the recommended procedure for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain a panel reactive antibody (PRA) screens to class I and class II antigens for all patients before HCT; if the PRA shows \> 10% activity, then flow cytometric or B and T cell cytotoxic cross matches should be obtained; the donor should be excluded if any of the cytotoxic cross match assays are positive; for those patients with an HLA class I allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be obtained regardless of the PRA results; a positive anti-donor cytotoxic crossmatch is an absolute donor exclusion * DONOR: Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-allele mismatch, i.e., the patient is A\*0101 and the donor is A\*0102, and this type of mismatch is not allowed * DONOR: Only filgrastim (G-CSF) mobilized PBSC only will be permitted as a hematopoietic stem cell (HSC) source on this protocol Exclusion Criteria: * Patients with rapidly progressive intermediate or high grade NHL * Patients with a diagnosis of chronic myelomonocytic leukemia (CMML) * Patients with refractory anemia with excess blasts (RAEB) who have not received myelosuppressive chemotherapy i.e. induction chemotherapy * Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy * Presence of circulating leukemic blasts (in the peripheral blood) detected by standard pathology for patients with AML, ALL or CML * Presence of \>= 5% circulating leukemic blasts (in the peripheral blood) detected by standard pathology for patients with MDS/MPS * Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment * Females who are pregnant or breast-feeding * Patients with active non-hematological malignancies (except non-melanoma skin cancers) or those with non-hematological malignancies (except non-melanoma skin cancers) who have been rendered with no evidence of disease, but have a greater than 20% chance of having disease recurrence within 5 years; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy * Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month * Cardiac ejection fraction \< 35% (or, if unable to obtain ejection fraction, shortening fraction of \< 26%); ejection fraction is required if age \> 50 years or there is a history of anthracycline exposure or history of cardiac disease; patients with a shortening fraction \< 26% may be enrolled if approved by a cardiologist * Diffusing capacity of the lung for carbon monoxide (DLCO) \< 40%, total lung capacity (TLC) \< 40%, forced expiratory volume in one second (FEV1) \< 40% and/or receiving supplementary continuous oxygen * The FHCRC PI of the study must approve of enrollment of all patients with pulmonary nodules * Patients with clinical or laboratory evidence of liver disease would be evaluated for the cause of liver disease, its clinical severity in terms of liver function, and the degree of portal hypertension; patients will be excluded if they are found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bridging fibrosis, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin \> 3 mg/dL, or symptomatic biliary disease * Karnofsky scores \< 60 or Lansky Score \< 50 * Patient has poorly controlled hypertension and on multiple antihypertensives * Human immunodeficiency virus (HIV) positive patients * Active bacterial or fungal infections unresponsive to medical therapy * All patients receiving antifungal therapy voriconazole, posaconazole, or fluconazole and who are then randomized to ARM 2 must have sirolimus reduced according to the Standard Practice Antifungal Therapy Guidelines * The addition of cytotoxic agents for "cytoreduction" with the exception of tyrosine kinase inhibitors (such as imatinib), cytokine therapy, hydroxyurea, low dose cytarabine, chlorambucil, or Rituxan will not be allowed within three weeks of the initiation of conditioning * DONOR: Donor (or centers) who will exclusively donate marrow * DONOR: Donors who are HIV-positive and/or, medical conditions that would result in increased risk for G-CSF mobilization and harvest of PBSC
healthy Volunteers
false
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive FLU IV over 30 minutes on days -4 to -2. Patients also receive CSP PO BID on days -3 to 96 with taper to day 150 and MMF PO TID daily on days 0-29 and then BID on days 30-150 with taper to day 180. Patients undergo allogeneic PBSCT on day 0 following the TBI.
    intervention Names
    1. Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    2. Drug: Cyclosporine
    3. Drug: Fludarabine Phosphate
    4. Drug: Mycophenolate Mofetil
    5. Procedure: Peripheral Blood Stem Cell Transplantation
    6. Radiation: Total-Body Irradiation
    label
    Arm I (MMF and CSP)
    type
    ACTIVE_COMPARATOR
  2. description
    Patients receive FLU and CSP as in Arm I and sirolimus PO QD on days -3 to 150 with taper to day 180. Patients also receive MMF PO TID on days 0-29 and then BID on days 30-40. MMF will then be discontinued without taper unless GVHD or disease relapse/progression occurs. Patients undergo allogeneic PBSCT on day 0 following the TBI.
    intervention Names
    1. Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    2. Drug: Cyclosporine
    3. Drug: Fludarabine Phosphate
    4. Drug: Mycophenolate Mofetil
    5. Procedure: Peripheral Blood Stem Cell Transplantation
    6. Drug: Sirolimus
    7. Radiation: Total-Body Irradiation
    label
    Arm II (MMF, CSP, and Sirolimus)
    type
    EXPERIMENTAL
  3. description
    Patients receive CSP orally (PO) twice daily (BID) on days -3 to 96 with taper to day 150 and and sirolimus PO once daily (QD) on days -3 to 150 with taper to day 180. Arm removed as of 14-Sep-2011
    intervention Names
    1. Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    2. Drug: Cyclosporine
    3. Drug: Fludarabine Phosphate
    4. Procedure: Peripheral Blood Stem Cell Transplantation
    5. Drug: Sirolimus
    6. Radiation: Total-Body Irradiation
    label
    Arm 0 (CSP and Sirolimus)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm 0 (CSP and Sirolimus)
    2. Arm I (MMF and CSP)
    3. Arm II (MMF, CSP, and Sirolimus)
    description
    Undergo allogeneic PBSCT
    name
    Allogeneic Hematopoietic Stem Cell Transplantation
    other Names
    1. allogeneic stem cell transplantation
    2. HSC
    3. HSCT
    type
    PROCEDURE
  2. arm Group Labels
    1. Arm 0 (CSP and Sirolimus)
    2. Arm I (MMF and CSP)
    3. Arm II (MMF, CSP, and Sirolimus)
    description
    Given PO or IV
    name
    Cyclosporine
    other Names
    1. 27-400
    2. Ciclosporin
    3. CsA
    4. Cyclosporin
    5. Cyclosporin A
    6. Gengraf
    7. Neoral
    8. OL 27-400
    9. Sandimmun
    10. Sandimmune
    11. SangCya
    type
    DRUG
  3. arm Group Labels
    1. Arm 0 (CSP and Sirolimus)
    2. Arm I (MMF and CSP)
    3. Arm II (MMF, CSP, and Sirolimus)
    description
    Given IV
    name
    Fludarabine Phosphate
    other Names
    1. 2-F-ara-AMP
    2. 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-
    3. Beneflur
    4. Fludara
    5. SH T 586
    type
    DRUG
  4. arm Group Labels
    1. Arm I (MMF and CSP)
    2. Arm II (MMF, CSP, and Sirolimus)
    description
    Given PO
    name
    Mycophenolate Mofetil
    other Names
    1. Cellcept
    2. MMF
    type
    DRUG
  5. arm Group Labels
    1. Arm 0 (CSP and Sirolimus)
    2. Arm I (MMF and CSP)
    3. Arm II (MMF, CSP, and Sirolimus)
    description
    Undergo allogeneic PBSCT
    name
    Peripheral Blood Stem Cell Transplantation
    other Names
    1. PBPC transplantation
    2. Peripheral Blood Progenitor Cell Transplantation
    3. Peripheral Stem Cell Support
    4. Peripheral Stem Cell Transplantation
    type
    PROCEDURE
  6. arm Group Labels
    1. Arm 0 (CSP and Sirolimus)
    2. Arm II (MMF, CSP, and Sirolimus)
    description
    Given PO
    name
    Sirolimus
    other Names
    1. AY 22989
    2. RAPA
    3. Rapamune
    4. RAPAMYCIN
    5. SILA 9268A
    6. WY-090217
    type
    DRUG
  7. arm Group Labels
    1. Arm 0 (CSP and Sirolimus)
    2. Arm I (MMF and CSP)
    3. Arm II (MMF, CSP, and Sirolimus)
    description
    Undergo TBI
    name
    Total-Body Irradiation
    other Names
    1. TOTAL BODY IRRADIATION
    2. Whole-Body Irradiation
    type
    RADIATION
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
174
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Number of patients with grades II-IV acute GVHD aGVHD Stages Skin: 1. a maculopapular eruption involving \< 25% BSA 2. a maculopapular eruption involving 25 - 50% BSA 3. generalized erythroderma 4. generalized erythroderma w/ bullous formation and often w/ desquamation Liver: 1. bilirubin 2.0 - 3.0 mg/100 mL 2. bilirubin 3 - 5.9 mg/100 mL 3. bilirubin 6 - 14.9 mg/100 mL 4. bilirubin \> 15 mg/100 mL Gut: Diarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients w/ visible bloody diarrhea are at least stage 2 gut and grade 3 overall. aGVHD Grades Grade II: Stage 1 - 2 skin w/ no gut/liver involvement Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 w/ extreme constitutional symptoms or death
    measure
    Number of Patients With Grades II-IV Acute GVHD
    time Frame
    At day 100 post-transplant
secondary Outcomes
  1. description
    Number of patients who developed chronic extensive GVHD post-transplant. The diagnosis of chronic GVHD requires at least one manifestation that is distinctive for chronic GVHD as opposed to acute GVHD. In all cases, infection and others causes must be ruled out in the differential diagnosis of chronic GVHD.
    measure
    Number of Patients With Chronic Extensive GVHD
    time Frame
    Up to 1 year
  2. description
    Number of patients with grades III-IV acute GVHD aGVHD Stages Skin: 1. a maculopapular eruption involving \< 25% BSA 2. a maculopapular eruption involving 25 - 50% BSA 3. generalized erythroderma 4. generalized erythroderma w/ bullous formation and often w/ desquamation Liver: 1. bilirubin 2.0 - 3.0 mg/100 mL 2. bilirubin 3 - 5.9 mg/100 mL 3. bilirubin 6 - 14.9 mg/100 mL 4. bilirubin \> 15 mg/100 mL Gut: Diarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients w/ visible bloody diarrhea are at least stage 2 gut and grade 3 overall. aGVHD Grades Grade II: Stage 1 - 2 skin w/ no gut/liver involvement Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 w/ extreme constitutional symptoms or death
    measure
    Number of Patients With Grades III-IV Acute GVHD
    time Frame
    Up to 100 days
  3. description
    Number of subjects expired without disease progression/relapse.
    measure
    Number of Non-Relapse Mortalities
    time Frame
    Up to 1 year
  4. description
    Number of subjects surviving overall post-transplant.
    measure
    Number of of Participants Surviving Overall
    time Frame
    Up to 1 year
  5. description
    Relapse/Progression criteria: CML New cytogenetic abnormality and/or development of accelerated phase or blast crisis. The criteria for accelerated phase will be defined as unexplained fever \>38.3°C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, marrow blasts and promyelocytes \>20%. AML, ALL, MDS \>5% blasts by morphologic or flow cytometric evaluation of the BMA or appearance of extramedullary disease CLL ≥1 of: Physical exam/imaging studies ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter's transformation. NHL \>25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions. MM ≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ treatment; or definite increase in the size or number of plasmacytomas or lytic bone lesions
    measure
    Number of Participants With Relapse/Progression
    time Frame
    Up to 1 year
Full study description
brief Summary
This randomized phase III trial studies how well graft-vs-host disease (GVHD) prophylaxis works in treating patients with hematologic malignancies undergoing unrelated donor peripheral blood stem cell transplant. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant (PBSCT) helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving total-body irradiation (TBI) together with fludarabine phosphate (FLU), cyclosporine (CSP), mycophenolate mofetil (MMF), or sirolimus before transplant may stop this from happening.
detailed Description
PRIMARY OBJECTIVES: I. To compare the effectiveness of 2 GVHD prophylaxis regimens in preventing acute grades II-IV GVHD. SECONDARY OBJECTIVES: I. Compare non-relapse mortality in the 2 arms. II. Compare survival and progression-free survivals in the 2 arms. OUTLINE: Patients are randomized to 1 of 2 treatment arms. All patients receive FLU intravenously (IV) over 30 minutes on days -4 to -2 followed by 2-3 Gy TBI on day 0. ARM 0: Patients receive CSP orally (PO) twice daily (BID) on days -3 to 96 with taper to day 150 and and sirolimus PO once daily (QD) on days -3 to 150 with taper to day 180. Arm removed as of 14-Sep-2011 ARM I: Patients receive CSP orally (PO) twice daily (BID) on days -3 to 96 with taper to day 150 and MMF PO three times daily (TID) on days 0-29 and then BID on days 30-150 with taper to day 180. ARM II: Patients receive CSP as in Arm I and sirolimus PO once daily (QD) on days -3 to 150 with taper to day 180. Patients also receive MMF PO TID on days 0-29 and then BID on days 30-40. MMF will then be discontinued without taper unless GVHD or disease relapse/progression occurs. TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 following the TBI. After completion of study treatment, patients are followed up periodically.
Source references
references
  1. citation
    Cooper JP, Storer BE, Granot N, Gyurkocza B, Sorror ML, Chauncey TR, Shizuru J, Franke GN, Maris MB, Boyer M, Bruno B, Sahebi F, Langston AA, Hari P, Agura ED, Lykke Petersen S, Maziarz RT, Bethge W, Asch J, Gutman JA, Olesen G, Yeager AM, Hubel K, Hogan WJ, Maloney DG, Mielcarek M, Martin PJ, Flowers MED, Georges GE, Woolfrey AE, Deeg JH, Scott BL, McDonald GB, Storb R, Sandmaier BM. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. Haematologica. 2021 Jun 1;106(6):1599-1607. doi: 10.3324/haematol.2020.248187.
    pmid
    32499241
    type
    DERIVED
  2. citation
    Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 2019 Aug;6(8):e409-e418. doi: 10.1016/S2352-3026(19)30088-2. Epub 2019 Jun 24.
    pmid
    31248843
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-02260df27affd6721170
      requested nct id
      NCT01231412
      primary nct id
      NCT01231412
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      payload sha256
      f19281eb990810e8e5638b9f262a9c3a0fdbd7612075d3d452ca98070961b6f0
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-02260df27affd6721170
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01231412
      occurrences
      1. context exact
        NCT01231412
        end
        11
        exact text
        NCT01231412
        start
        0
      offset unit
      unicode_code_points
      query cond
      Peripheral T-Cell Non-Hodgkin Lymphoma
      query disease state id
      ds-peripheral-t-cell-non-hodgkin-lymphoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      source json pointer
      /studies/51/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      5d75336cd8917c795a8c22c956338f670fdd74f86b7d4833c4e1d1f9d0c109ba
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-8e1b3664b141853cbcc9
      requested nct id
      NCT01231412
      primary nct id
      NCT01231412
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      1c4fd3e0811df44b5e0f5df52e7dfae23c9fcc641ee4104710fa16eab7cef08f
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-8e1b3664b141853cbcc9
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01231412
      occurrences
      1. context exact
        NCT01231412
        end
        11
        exact text
        NCT01231412
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/428/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      5d75336cd8917c795a8c22c956338f670fdd74f86b7d4833c4e1d1f9d0c109ba

    Preserved source evidence · Not medical advice